Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab for Recurrent, Metastatic Nasopharyngeal Carcinoma
NCT02875613Phase 2Terminated
- Start
- Jan 2017
- Primary completion
- Apr 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in nasopharyngeal carcinoma (NPC). Started Jan 2017; status: terminated.
02
Drugs
avelumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02875613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02875613.